Are there clinically significant differences between dopamine agonists.
Stocchi
Fabrizio
F
Institute of Neurology IRCCS Neuromed (Is), University La Sapienza, Rome, Italy.
Vacca
Laura
L
Onofrj
Marco
M
D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D002986:Clinical Trials as Topic; D006970:Disorders of Excessive Somnolence / Q000139:chemically induced / Q000503:physiopathology; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D004409:Dyskinesia, Drug-Induced / Q000503:physiopathology / Q000517:prevention & control; D006801:Humans; D007980:Levodopa / Q000009:adverse effects; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D011954:Receptors, Dopamine / Q000187:drug effects / Q000378:metabolism
D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D011954:Receptors, Dopamine; D007980:Levodopa